Interferon beta-1a: Clinical Trials

147 trials of Interferon beta-1a, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

110 completed, 12 terminated, 9 unknown, 9 withdrawn. 34 Phase 2, 34 Phase 3, 34 Phase 4, 16 Phase 1, 4 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 234Completed 23, Unknown 5, Withdrawn 3, Terminated 2, Recruiting 1
Phase 334Completed 24, Terminated 5, Active not recruiting 2, Recruiting 1, Unknown 1, Withdrawn 1
Phase 434Completed 25, Withdrawn 4, Terminated 3, Active not recruiting 1, Unknown 1
Phase 116Completed 14, Unknown 1, Withdrawn 1
Not applicable4Completed 4
Early Phase 11Completed 1

Follow Interferon beta-1a: new trials by email Literature Review of Interferon beta-1a trials Research Report on Interferon beta-1a

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2WithdrawnFred Hutchinson Cancer Center2025-04-012024-07-12
Early Interferon-beta Treatment for West-Nile Virus Infection
Rebif 44 MCG Per 0.5 ML Prefilled Syringe, Saline - West Nile Virus, West Nile Fever Encephalitis
Phase 2UnknownTel-Aviv Sourasky Medical Center1002024-07-142024-07-23
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited) - Multiple Sclerosis (MS)
Active not recruitingBayer42024-03-202026-07-06
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Diroximel Fumarate, Avonex, Tysabri - Multiple Sclerosis
RecruitingBiogen9082023-10-272026-08-11
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
Nivolumab, Cisplatin, 5-Fluorouracil - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Phase 2RecruitingGerman Society for Pediatric Oncology and Hematology GPOH gGmbH572023-01-102024-05-16
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients
MetFORMIN 1000 Mg Oral Tablet, Interferon beta-1a - Multiple Sclerosis
Phase 2UnknownGerman University in Cairo802022-02-012023-03-20
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis
Phase 2WithdrawnBiogen2021-06-302023-06-01
World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments
Remdesivir, Acalabrutinib, Interferon beta-1a - Covid19
Phase 3UnknownThe University of The West Indies1002021-06-012021-05-13
the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19
High dose Interferon-beta 1a, Lopinavir/Ritonavir, Low dose Interferon-beta 1a - Covid19
Phase 2UnknownShahid Beheshti University of Medical Sciences1002020-08-202020-08-20
Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
Interferon beta-1a, Placebo, Remdesivir - COVID-19
Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)9692020-08-052022-03-14
Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic
Convalescent Plasma Transfusion, Hydroxychloroquine, DAS181 - COVID-19
UnknownQassim University2002020-07-252020-07-07
Public Health Emergency: SOLIDARITY TRIAL Philippines
Remdesivir, Hydroxychloroquine, Lopinavir / Ritonavir - Covid19
Not applicableCompletedUniversity of the Philippines13142020-04-232022-03-02
Interferon Beta 1a in Hospitalized COVID-19 Patients
Interferon Beta-1A, Lopinavir / Ritonavir, Single Dose of Hydroxychloroquine - COVID-19
Phase 4UnknownShahid Beheshti University of Medical Sciences402020-04-152020-04-20
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
Hydroxychloroquine, Lopinavir / Ritonavir, Interferon Beta-1A - COVID-19
Phase 2CompletedShahid Beheshti University of Medical Sciences602020-04-092020-05-05
Trial of Treatments for COVID-19 in Hospitalized Adults
Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A - Corona Virus Infection
Phase 3CompletedInstitut National de la Santé Et de la Recherche Médicale, France15522020-03-222026-07-08
Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products
Interferon beta-1a, Peginterferon beta-1a, Placebo - Healthy Subjects, Pharmacokinetics
Phase 1CompletedFood and Drug Administration (FDA)842020-02-282024-04-22
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
BIIB017 (peginterferon beta-1a), Interferon beta type 1a - Multiple Sclerosis, Relapsing-Remitting
Phase 3Active not recruitingBiogen1522019-10-182026-09-24
Study of Evobrutinib in Participants With RMS
Evobrutinib, Avonex®, Avonex® matched Placebo - Relapsing-remitting Multiple Sclerosis
Phase 3TerminatedEMD Serono Research & Development Institute, Inc.12019-09-102021-08-05
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
Evobrutinib, Avonex®, Avonex® matched Placebo - Relapsing-remitting Multiple Sclerosis
Phase 3TerminatedEMD Serono Research & Development Institute, Inc.32019-08-262021-08-05
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting
Phase 4Active not recruitingThe Cleveland Clinic8002019-01-032026-08-31

Showing 20 of 147. Sign in to see all of them.

Conditions studied

Multiple Sclerosis (77)  ·  Multiple Sclerosis, Relapsing-Remitting (53)  ·  COVID-19 (9)  ·  Recurrence (4)  ·  Autoimmune Diseases (2)  ·  Colitis, Ulcerative (2)  ·  Demyelinating Diseases (2)  ·  Inflammation (2)  ·  Optic Neuritis (2)  ·  Pneumonia (2)  ·  Alzheimer Disease (1)  ·  Asthma (1)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Bone Diseases, Metabolic (1)  ·  Burkitt Lymphoma (1)

Sponsors

Biogen (38)  ·  Merck KGaA, Darmstadt, Germany (23)  ·  EMD Serono (9)  ·  Biocad (4)  ·  Novartis Pharmaceuticals (4)  ·  Sanofi (4)  ·  Bayer (3)  ·  EMD Serono Research & Development Institute, Inc. (3)  ·  Genzyme, a Sanofi Company (3)  ·  Shahid Beheshti University of Medical Sciences (3)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (3)  ·  Celgene (2)  ·  Centre Hospitalier Universitaire Vaudois (2)  ·  Faron Pharmaceuticals Ltd (2)  ·  Hoffmann-La Roche (2)

Countries

United States (61)  ·  Germany (36)  ·  United Kingdom (29)  ·  Italy (28)  ·  Canada (27)  ·  Russia (25)  ·  Spain (24)  ·  France (23)  ·  Czechia (20)  ·  Poland (18)  ·  Belgium (16)  ·  Australia (15)  ·  Finland (14)  ·  Serbia (14)  ·  Sweden (14)

Top investigators

Dr. Norbert Zessack (3)  ·  Claudia Pena Rossi, M.D. (2)  ·  Ilad Alavi Darazam, MD (2)  ·  Ivan Sardaryan, PhD (2)  ·  Minoosh Shabani, MD (2)  ·  Mohammadreza Haji Esmaelie, MD (2)

Results publications

PMID 30144037, PMID 34473343, PMID 34882037, PMID 36163349, PMID 36695483, PMID 37272540, PMID 37652990, PMID 22622860, PMID 27423899, PMID 27590291, PMID 28002679, PMID 31654272, PMID 31675266, PMID 31762387, PMID 32511687, PMID 32690791, PMID 32710396, PMID 33414927, PMID 33724637, PMID 34035833, PMID 34350582, PMID 34904871, PMID 35672926, PMID 36619856, PMID 36792367, PMID 37148240, PMID 37745914, PMID 39290861, PMID 39935588, PMID 39965438, PMID 40258203, PMID 40462564, PMID 40554392, PMID 40629721, PMID 42832215, PMID 15714427, PMID 17654600, PMID 18071030, PMID 18789766, PMID 18946064, PMID 19145731, PMID 19302707, PMID 20542736, PMID 20659956, PMID 21397567, PMID 21742556, PMID 21960587, PMID 21988668, PMID 21999176, PMID 22047971

NIH funding

2014 (4), 2018 (3), 2009 (2), 2016 (2), 2023 (2), 2004 (1), 2005 (1), 2008 (1), 2015 (1), 2017 (1), 2019 (1), U01NS045719 (1)